Medtronic plc. (NYSE:MDT) EVP Bryan C. Hanson sold 16,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $82.82, for a total value of $1,325,120.00. Following the completion of the transaction, the executive vice president now directly owns 88,818 shares of the company’s stock, valued at $7,355,906.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Bryan C. Hanson also recently made the following trade(s):
- On Thursday, November 16th, Bryan C. Hanson sold 16,000 shares of Medtronic stock. The shares were sold at an average price of $79.02, for a total value of $1,264,320.00.
Shares of Medtronic plc. (NYSE MDT) opened at $82.04 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. Medtronic plc. has a 12-month low of $69.35 and a 12-month high of $89.72. The company has a market capitalization of $113,017.08, a P/E ratio of 18.00, a P/E/G ratio of 2.30 and a beta of 1.00.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 19th. Investors of record on Friday, December 29th will be given a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a dividend yield of 2.24%. The ex-dividend date is Thursday, December 28th. Medtronic’s payout ratio is 50.41%.
A number of research analysts have issued reports on the company. BMO Capital Markets boosted their price target on Medtronic to $94.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. SunTrust Banks reissued a “buy” rating and issued a $96.00 price target on shares of Medtronic in a report on Monday, October 2nd. Jefferies Group reissued a “buy” rating and issued a $96.00 price target on shares of Medtronic in a report on Thursday, September 28th. Argus raised Medtronic from a “hold” rating to a “buy” rating and upped their target price for the stock from $81.27 to $95.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. Finally, UBS reaffirmed an “overweight” rating on shares of Medtronic in a research note on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Medtronic currently has an average rating of “Hold” and an average target price of $88.57.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Medtronic by 2.4% during the second quarter. Vanguard Group Inc. now owns 104,776,036 shares of the medical technology company’s stock worth $9,298,872,000 after purchasing an additional 2,454,380 shares in the last quarter. BlackRock Inc. grew its holdings in Medtronic by 2.8% in the 2nd quarter. BlackRock Inc. now owns 89,512,229 shares of the medical technology company’s stock valued at $7,944,210,000 after buying an additional 2,476,853 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Medtronic by 3.0% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 58,646,070 shares of the medical technology company’s stock valued at $4,724,526,000 after buying an additional 1,729,715 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Medtronic by 1.1% in the 3rd quarter. Artisan Partners Limited Partnership now owns 23,853,034 shares of the medical technology company’s stock valued at $1,855,050,000 after buying an additional 269,814 shares in the last quarter. Finally, Lazard Asset Management LLC grew its holdings in Medtronic by 43.8% in the 2nd quarter. Lazard Asset Management LLC now owns 19,669,866 shares of the medical technology company’s stock valued at $1,745,699,000 after buying an additional 5,991,094 shares in the last quarter. Hedge funds and other institutional investors own 81.74% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/12/20/bryan-c-hanson-sells-16000-shares-of-medtronic-plc-mdt-stock.html.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.